176 related articles for article (PubMed ID: 20713089)
1. Development of a simple system for screening anti-hepatitis C virus drugs utilizing mutants capable of vigorous replication.
Yu L; Aoki C; Shimizu Y; Shimizu K; Hou W; Yagyu F; Wen X; Oshima M; Iwamoto A; Gao B; Liu W; Gao GF; Kitamura Y
J Virol Methods; 2010 Nov; 169(2):380-4. PubMed ID: 20713089
[TBL] [Abstract][Full Text] [Related]
2. A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication.
Wu Y; Liao Q; Yang R; Chen X; Chen X
Virus Res; 2011 Feb; 155(2):406-14. PubMed ID: 21144873
[TBL] [Abstract][Full Text] [Related]
3. Development of a robust luciferase reporter 1b/2a hepatitis C virus (HCV) for characterization of early stage HCV life cycle inhibitors.
Chan K; Robinson M; Yang H; Cornew S; Delaney Iv WE
Antiviral Res; 2013 Apr; 98(1):85-92. PubMed ID: 23376631
[TBL] [Abstract][Full Text] [Related]
4. A recombinant replication-competent hepatitis C virus expressing Azami-Green, a bright green-emitting fluorescent protein, suitable for visualization of infected cells.
Hou W; Aoki C; Yu L; Wen X; Xue Y; Gao B; Liu W; Gao GF; Iwamoto A; Kitamura Y
Biochem Biophys Res Commun; 2008 Dec; 377(1):7-11. PubMed ID: 18786508
[TBL] [Abstract][Full Text] [Related]
5. Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment.
Chang JH; Kato N; Muroyama R; Taniguchi H; Guleng B; Dharel N; Shao RX; Tateishi K; Jazag A; Kawabe T; Omata M
Liver Int; 2010 Feb; 30(2):311-8. PubMed ID: 19840259
[TBL] [Abstract][Full Text] [Related]
6. A cell culture adapted HCV JFH1 variant that increases viral titers and permits the production of high titer infectious chimeric reporter viruses.
Liu S; Xiao L; Nelson C; Hagedorn CH
PLoS One; 2012; 7(9):e44965. PubMed ID: 23028707
[TBL] [Abstract][Full Text] [Related]
7. Renilla luciferase-based quantitation of Potato virus A infection initiated with Agrobacterium infiltration of N. benthamiana leaves.
Eskelin K; Suntio T; Hyvärinen S; Hafren A; Mäkinen K
J Virol Methods; 2010 Mar; 164(1-2):101-10. PubMed ID: 20026122
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea as an inhibitor of hepatitis C virus RNA replication.
Nozaki A; Morimoto M; Kondo M; Oshima T; Numata K; Fujisawa S; Kaneko T; Miyajima E; Morita S; Mori K; Ikeda M; Kato N; Tanaka K
Arch Virol; 2010 Apr; 155(4):601-5. PubMed ID: 20204428
[TBL] [Abstract][Full Text] [Related]
9. Evaluation systems for anti-HCV drugs.
Moriishi K; Matsuura Y
Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of a stable luciferase dengue virus for high-throughput screening.
Zou G; Xu HY; Qing M; Wang QY; Shi PY
Antiviral Res; 2011 Jul; 91(1):11-9. PubMed ID: 21575658
[TBL] [Abstract][Full Text] [Related]
11. A cell-based bicistronic lentiviral reporter system for identification of inhibitors of the hepatitis C virus internal ribosome entry site.
Lourenço S; Boni S; Furling D; Cosset FL; Cahour A
J Virol Methods; 2009 Jun; 158(1-2):152-9. PubMed ID: 19428584
[TBL] [Abstract][Full Text] [Related]
12. Measuring antiviral activity of benzimidazole molecules that alter IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase.
Liu S; Nelson CA; Xiao L; Lu L; Seth PP; Davis DR; Hagedorn CH
Antiviral Res; 2011 Jan; 89(1):54-63. PubMed ID: 21075143
[TBL] [Abstract][Full Text] [Related]
13. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses.
Gottwein JM; Scheel TK; Hoegh AM; Lademann JB; Eugen-Olsen J; Lisby G; Bukh J
Gastroenterology; 2007 Nov; 133(5):1614-26. PubMed ID: 17983807
[TBL] [Abstract][Full Text] [Related]
14. Novel HCV replication mouse model using human hepatocellular carcinoma xenografts.
Guévin C; Lamarre A; Labonté P
Antiviral Res; 2009 Oct; 84(1):14-22. PubMed ID: 19622372
[TBL] [Abstract][Full Text] [Related]
15. Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant.
Kaul A; Woerz I; Meuleman P; Leroux-Roels G; Bartenschlager R
J Virol; 2007 Dec; 81(23):13168-79. PubMed ID: 17881454
[TBL] [Abstract][Full Text] [Related]
16. Thermostable hepatitis C virus JFH1-derived variant isolated by adaptation to Huh7.5.1 cells.
Shirasago Y; Fukazawa H; Aizaki H; Suzuki T; Suzuki T; Sugiyama K; Wakita T; Hanada K; Abe R; Fukasawa M
J Gen Virol; 2018 Oct; 99(10):1407-1417. PubMed ID: 30045785
[TBL] [Abstract][Full Text] [Related]
17. High-throughput screening of HCV RNA replication inhibitors by means of a reporter replicon system.
Hao W; Duggal R
Methods Mol Biol; 2009; 510():243-50. PubMed ID: 19009266
[TBL] [Abstract][Full Text] [Related]
18. Monitoring the antiviral effect of alpha interferon on individual cells.
Kim CS; Jung JH; Wakita T; Yoon SK; Jang SK
J Virol; 2007 Aug; 81(16):8814-20. PubMed ID: 17537862
[TBL] [Abstract][Full Text] [Related]
19. A new living cell-based assay system for monitoring genome-length hepatitis C virus RNA replication.
Dansako H; Ikeda M; Abe K; Mori K; Takemoto K; Ariumi Y; Kato N
Virus Res; 2008 Oct; 137(1):72-9. PubMed ID: 18602954
[TBL] [Abstract][Full Text] [Related]
20. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection.
Jensen TB; Gottwein JM; Scheel TK; Hoegh AM; Eugen-Olsen J; Bukh J
J Infect Dis; 2008 Dec; 198(12):1756-65. PubMed ID: 19032070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
